Solid Data For Sarepta’s Next-Gen PPMO Treatment But Future Uncertain
Executive Summary
A Phase II study testing a next-generation exon skipping medicine vesleteplirsen in Duchenne muscular dystrophy amendable to exon 51 outpaced Sarepta’s Exondys 51.